Compare Invesco DB Oil Fund (DBO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Quest Diagnostics Inc — how do they compare? Invesco DB Oil Fund trades at $19.88, while Quest Diagnostics Inc trades at $205.45 (market cap $22.80B). The key difference: Quest Diagnostics Inc pays a 1.67% dividend while Invesco DB Oil Fund pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| DBO | DGX | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $216.02 |
52-Week Low | $11.98 | $166.42 |
Market Cap | — | $22.80B |
Enterprise Value | — | $28.82B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO is trading at $19.59, up 8.47% with strong bullish momentum driven by escalating Middle East tensions that are boosting oil prices. Technical indicators show a bullish trend with support at $19 and resistance at $20, though RSI suggests potential overbought conditions. The stock benefits from geopolitical events that typically drive energy sector performance.
The outlook remains positive as oil price strength translates to potential revenue growth for US energy companies. Key risks include geopolitical volatility and potential supply disruptions. Analyst sentiment appears constructive given the favorable oil market dynamics, though fundamental metrics require verification from recent SEC filings.
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
